Hormone therapy has endured a rather bumpy history after the Women’s Health Initiative published clinical trial data in 2002 ...

The agency told Bayer it needs additional time to review the non-hormonal drug, called elinzanetant. Regulators in Canada and ...

The Food and Drug Administration (FDA) has extended the review period for elinzanetant, an investigational hormone-free therapy for the treatment of moderate to severe vasomotor symptoms (VMS) due to ...

The panelists said that vaginal creams and other localized therapies for menopause are safe and vastly underused by women who ...

A Food and Drug Administration expert panel has reignited a debate over whether hormone therapy should be used to treat ...

Members of an FDA expert panel discussed reassessing boxed warnings for menopausal HT and how to better educate patients and ...

Bayer (OTCPK:BAYZF) (OTCPK:BAYRY) (OTCPK:BAMXF) said it has received notification from the FDA regarding an extension of the ...

Simultaneously, Bayer is making significant headway with its cancer medication Sevabertinib. The company has applied for regulatory approval in China, where the drug has already received the coveted ...

A decades-old label has scared women (and their doctors) away from safe and effective menopause treatment. That could finally change today.

A panel of 12 experts in the menopause field reexamined the findings of the 2002 Women’s Health Initiative study that said ...

Bioidentical or plant-derived hormones have uncertain efficacy or safety in treating menopausal symptoms. What is the evidence supporting the use of compounded and FDA-approved bioidentical products?